cerca CERCA
Giovedì 28 Marzo 2024
Aggiornato: 19:07
10 ultim'ora BREAKING NEWS

Comunicato stampa

Proteomics International Laboratories Ltd Produced and Validated a Ground-breaking Predictive Test for the Diagnosis of Diabetic Kidney disease (DKD)

09 giugno 2015 | 10.48
LETTURA: 2 minuti

PERTH, Australia, June 9, 2015 /PRNewswire/ --

Highlights

Market potential

The commercial benefits, medical benefits and cost savings in commercialising the test are enormous. In Australia alone, the total cost to the health system and in productivity loss from diabetes is estimated at AUD$10.3b annually. The potential for pharmaceutical companies to market test to identify at-risk patient groups and then provide drugs to treat those patients may provide PIQ with substantial returns from licensing fees and royalties. The test may be commercialised simply using today's standard pathology laboratory assay systems. The global market for diagnostic kits is substantial; in the US the pathology lab industry is composed of 23,803 businesses with total annual revenue of US$55b.

Background

The test was developed using PIQ's world-leading proprietary proteomics platform to measure specific biomarkers (biological signatures) in the blood of patients with diabetes to determine the likelihood of those patients contracting DKD. Via its mass spectrometry-based proteomics technology, PIQ has developed a deeper understanding of DKD beyond classical pathology, by comparing the differences in the protein makeup of people with and without the disease

Study Results

The test was developed in a AUD$2 million clinical study of 576 patients with diabetes, from 2010 - 2014 in Western Australia. The results show it can predict:

Specifically, the clinical study found that 10% of the patients had a significant and rapid decline in kidney function over the four year study period and that the test correctly predicted 67% of these individuals.

www.proteomicsinternational.com

Riproduzione riservata
© Copyright Adnkronos
Tag
Vedi anche


SEGUICI SUI SOCIAL



threads whatsapp linkedin twitter youtube facebook instagram
ora in
Prima pagina
articoli
in Evidenza